Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies
Frontiers in Allergy · 01.04.2026 · 7
DOI: 10.3389/falgy.2026.1761840 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Allergy, online erschienen am 01.04.2026. Verfasst von Siu-Jung Au Yong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Bandar Sunway, Malay…. Die Arbeit nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Allergic rhinitis (AR) is a common inflammatory disorder of the upper airway that is primarily managed with pharmacotherapy, biologics and allergen immunotherapy. However, a substantial proportion of patients experience incomplete or insufficient symptom control, treatment-related adverse effects, or poor adherence. Increasing evidence has linked AR with alterations in microbial composition across multiple mucosal sites, including the gut, highlighting potential roles for host-microbiome interactions in the regulation of allergic inflammation, although causal relationships remain incompletely defined. This narrative mini-review synthesizes current evidence on gut microbiome-based interventions for allergic rhinitis (AR), including probiotics, prebiotics, synbiotics, postbiotics, and emerging approaches such as fecal microbiota transplantation, engineered microbes, and bacteriophage-based therapies. It examines proposed immunological mechanisms involving type 2 inflammation, regulatory immune pathways, and gut–airwa y axis signalling, while distinguishing clinically evaluated strategies from experimental or preclinical and assessing their translational readiness. Collectively, available evidence suggests that microbiome-targeted therapies represent a promising conceptual avenue for understanding and potentially modulating AR. However, their clinical application remains constrained by heterogeneous study designs, reliance on extrapolated data from preclinical studies, limited standardized outcome measures, insufficient long-term safety data, and evolving regulatory frameworks. Addressing these challenges through well-designed clinical trials and improved mechanistic characterization will be essential to clarify the role of microbiome-based interventions as adjunctive strategies in AR management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia.
- School of Pharmacy, Sunway University, Bandar Sunway, Malaysia.
- Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Zitieren
APA
Au Yong, S. J., Lestari Lee, A. S., Subramaniyan, V., Long, C. M., Husain, S., Reginald, K., & Ser, H. L. (2026). Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies. Frontiers in Allergy, 7. https://doi.org/10.3389/falgy.2026.1761840
Vancouver
Au Yong SJ, Lestari Lee AS, Subramaniyan V, Long CM, Husain S, Reginald K, et al. Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies. Frontiers in Allergy. 2026;7. doi:10.3389/falgy.2026.1761840
BibTeX
@article{AuYong2026,
author = {Au Yong, Siu-Jung and Lestari Lee, Amanda Sandra and Subramaniyan, Vetriselvan and Long, Chiau Ming and Husain, Salina and Reginald, Kavita and Ser, Hooi-Leng},
title = {Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies},
journal = {Frontiers in Allergy},
year = {2026},
volume = {7},
doi = {10.3389/falgy.2026.1761840}
}
EUVIMED